Bryan, Garnier & Co. announces successful admission of ONI BioPharma Inc.’s common stock to listing and trading on NYSE Alternext Paris
Share the transaction
Paris, December 15th 2008 – Bryan, Garnier & Co, the independent pan-European investment bank focused on growth companies, today announced the admission of ONI BioPharma Inc.’s common stock to listing and trading on NYSE Alternext Paris (NYSE Alternext Paris – ALONI – US6840231046). The company was previously listed on the American Stock Exchange (Alternext US).
This new listing will make ONI BioPharma the first US-based company to have its shares listed on Alternext Paris, beginning December 15, 2008.
Bryan, Garnier & Co. acted as sole listing sponsor and exclusive advisor to the company.
The transaction enables ONI BioPharma to get access to European stock markets and increase its investor coverage. It also demonstrates ONI’s confidence in the success of the launching of its first probiotic product (EvoraPlustm) and its willingness to be seen as a major and long-term player through the future marketing of its other products in the United States and internationally.
Established in 1996, ONI BioPharma is an early-stage biotechnology company aimed at adding value to novel technologies and products sourced from innovative research from internal discovery, at the University of Florida, at other academic centers, and from in-licensing from other biotechnology companies. ONI’s strategy is first to in-license or internally discover products and technologies, second to develop products up to and through human proof-of-concept studies (Phase II clinical trials of the U.S. Food and Drug Administration’s regulatory process), and third to partner with major pharmaceutical, biotechnology, or healthcare product firms for advanced clinical development and commercialization.
Virginie Lazès, Managing Partner at Bryan, Garnier & Co commented: “ONI BioPharma exemplifies the type of growth business we support at Bryan, Garnier & Co. This successful transaction demonstrates the ability of our experienced investment bankers to provide industry-specific advice and deliver solutions to our clients despite challenging capital markets. This operation confirms our position as a leading European investment bank in Healthcare.”
According to Christian Finan, Equity Capital Market Director at Bryan, Garnier & Co. “Providing ONI BioPharma with a European listing, will enable the company to enhance liquidity in its share price, and increase visibility for financing the future development of the company.”
Following eight other capital market operations since the beginning of 2008, this transaction confirms the leadership of Bryan, Garnier & Co with regards to the financing and capital raising of European growth companies. Since 1998, Bryan, Garnier & Co has successfully led more than 50 fundraisings for growth companies, having raised several hundred million Euros over the past few years thanks to an experienced team of investment bankers and sector specialists, who share with the bank’s clients their insightful knowledge of new technologies and capital markets.
Stanley B. Stein, Chief Executive Officer of ONI Biopharma, added: “We are delighted with the success of the listing on NYSE Alternext Paris. Bryan, Garnier & Co.’s capital markets experience and strong understanding of biotechnology business was primordial. It enabled us to carry out this novel transaction for a US growth company, in an extremely complicated financial environment. Overall, Bryan, Garnier & Co’s intervention combined a strong coordination of the transactional process with senior involvement.”
About ONI BioPharma
ONI BioPharma Inc. is a biopharmaceutical company engaged in developing unique proprietary technologies, some of which are being commercialized and sold in the over-the-counter consumer healthcare market. The Company also has a number of products in discovery, preclinical and clinical development, with a concentration in the main therapeutic area of infectious diseases, diagnostics, and oral health. The Company has developed platform technologies for future products, which the Company expects to develop.